Skip to main content
news
REUTERS/Tingshu Wang

Cooley, CYL & Partners and DeHeng Law Offices have advised China’s Asymchem Laboratories on its HK$6.85 billion ($878 million) secondary listing in Hong Kong, with Latham & Watkins and JunHe representing the joint sponsors.

This is believed to be the biggest healthcare IPO in Hong Kong this year. The company has been listed on the Shenzhen Stock Exchange since 2016.

Asymchem is a Chinese contract development manufacturing organisation (CDMO) serving the global pharmaceutical industry. According to Frost & Sullivan, it is the world’s fifth-largest drug substance CDMO by revenue, and the largest China-based commercial stage chemical drug CDMO.

The Cooley team was led by partners Yiming Liu and Michael Yu.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

Khaitan, SAM, Sidley advise on Torrent Power’s $413 mln QIP

by Nimitt Dixit |

Indian law firm Khaitan & Co has advised Torrent Power on its equity offering of $413 million through a qualified institutional placement of shares. Shardul Amarchand Mangaldas & Co and Sidley Austin advised the bookrunning lead managers on the deal.

Deals

IndusLaw guides Zepto’s $350 mln funding round

by Nimitt Dixit |

IndusLaw has guided Indian quick commerce company Zepto on its latest $350 million funding round led by Motilal Oswal's Private Wealth division.

Deals

9 firms advise on milestone $8.2 bln cross-border insurance deal

by Sarah Wong |

Global law firms Debevoise & Plimpton, Kirkland & Ellis and Herbert Smith Freehills are acting for Bermuda-based insurer Resolution Life on its $8.2 billion sale to Japan’s Nippon Life Insurance, the largest overseas acquisition by a Japanese insurer to date.